GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » GF Value Rank

MedMira (MedMira) GF Value Rank : 0 (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is MedMira GF Value Rank?

MedMira has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


MedMira GF Value Rank Related Terms

Thank you for viewing the detailed overview of MedMira's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports Third Quarter Results FY2021

By GlobeNewswire GlobeNewswire 06-30-2021

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

MedMira Reports First Quarter Results FY2021

By GlobeNewswire GlobeNewswire 12-25-2020

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019